CABLES1 and neoplasm: Regarding CABLES1, inactivating mutations have been reported in corticotropinomas, especially larger macroadenomas and predominantly in pediatric or early-onset cases, although these mutations may represent a tumor predisposition mechanism rather than a direct driver of resistance to therapy, making their role as a predictive biomarker uncertain.